NeoStem Reports Third-Data Safety Monitoring Board Review of PreSERVE AMI Trial

NeoStem, Inc. (Nasdaq: NBS ) ("NeoStem" or the "Company"), a leader in the fast growing cell therapy market, today announced that, on September 13, 2013, the Data Safety Monitoring Board ("DSMB") recommended continuing the PreSERVE AMI Phase 2 clinical trial following a third interim data and safety review. The PreSERVE trial of AMR-001 is